Involvement of mu, delta and kappa receptors in morphine-induced tolerance in the guinea pig myenteric plexus.
Tolerance in the longitudinal muscle-myenteric plexus (LM-MP) preparation to opioids appears to represent two separate phenomena. One phenomenon is characterized by marked subsensitivity to mu-selective opioid substances and a very short half-life. The other is characterized by moderate subsensitivity to morphine and to several nonopioid inhibitory substances and has a long half-life. The present investigation was to determine if the long half-life type of tolerance involves cross-tolerance between mu-selective opioids, such as morphine, and opioids selective for delta or kappa receptors. Tolerance was induced by s.c. implantation of morphine pellets for 7 days. Control guinea pigs received placebo pellets. Isolated LM-MP preparations were tolerant to the mu-selective agonists morphine and [D-Ala2,N-Me-Phe4,Gly5-ol]enkephalin as well as to [D-Ala,2D-Leu5]enkephalin and [D-Ser2]leucine enkephalin-Thr, agonists only slightly selective for delta receptors over mu. The delta-selective agonist, [D-Pen2,D-Pen3]enkephalin, produced a biphasic concentration-response curve. The first phase, which included only very weak effects, presumably represented delta-mediated effects. The second phase reached virtually 100% inhibition of the twitch. Significant subsensitivity (tolerance) was demonstrated only for the second phase, presumably representing mu-mediated effects. There was no significant tolerance to the kappa-selective agonist, U50,488H. Consistent with the literature, the results indicate effective twitch inhibition mediated by mu and kappa receptors, but not delta receptors. Among opioids, tolerance induced by morphine pellets in the LM-MP is limited to mu receptor-mediated inhibition.(ABSTRACT TRUNCATED AT 250 WORDS)
Leedham
J A
JA
Department of Pharmacology and Toxicology, West Virginia University, Health Sciences Center, Morgantown.
Bennett
L E
LE
Taylor
D A
DA
Fleming
W W
WW
D000818:Animals; D004361:Drug Tolerance; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D016308:Enkephalin, Leucine-2-Alanine / Q000494:pharmacology; D004745:Enkephalins / Q000494:pharmacology; D006168:Guinea Pigs; D008297:Male; D009020:Morphine / Q000494:pharmacology*; D009130:Muscle, Smooth / Q000187:drug effects; D009197:Myenteric Plexus / Q000187:drug effects*; D011957:Receptors, Opioid / Q000187:drug effects*; D017465:Receptors, Opioid, delta; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu
D004745:Enkephalins; D011957:Receptors, Opioid; D017465:Receptors, Opioid, delta; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D016308:Enkephalin, Leucine-2-Alanine; D009020:Morphine